Department of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China.
Department of Neurosurgery, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201803, China.
J Tradit Chin Med. 2023 Apr;43(2):286-294. doi: 10.19852/j.cnki.jtcm.20220928.002.
To investigate the efficacy and mechanisms of Dingxian pill combined with valproic acid (VPA) on pentylenetetrazol-induced chronical epilepsy in rats.
A rat model of epilepsy was established by administering pentylenetetrazol (PTZ) water solution (35 mg/kg). Rats were divided into 4 groups, among which three groups were treated with different drugs once a day for 28 d including Dingxian pill (2.4 g/kg), VPA (0.2 g/kg), or a combination of Dingxian pill (2.4 g/kg) and VPA (0.2 g/kg) respectively, and the control group was given the same volume of saline. Rats in different groups were compared based on animal behavior, electroencephalograms, Morris water maze, immunohistochemistry, transcriptomics and real-time polymerase chain reaction.
The combination therapy of Dingxian pill and VPA inhibited PTZ-induced seizure-like behavior and reduced seizure grades more significantly than VPA alone. Compared with the control group, the learning and memory ability of chronic PTZ-induced epileptic rats was improved in all the drug treatment groups, especially in the group that received both Dingxian pill and VPA. Similar to the results of MWM tests, expression of the neuroexcitability marker gene c-Fos was reduced after Dingxian pill and/or VPA treatment, and the effect was most pronounced in the combined treatment group. Transcriptomic analysis revealed that gene expression in the rodent hippocampus, which is involved in epilepsy, was upregulated by combined treatment with Dingxian pill and VPA, compared with VPA treatment alone.
Our results not only highlight the anti-epileptic effects of combined Dingxian pill and VPA treatment, but also shed light on the underlying molecular mechanisms and provide a way to apply Traditional Chinese Medicine in the treatment of epilepsy.
研究定痫丸联合丙戊酸钠(VPA)对戊四氮(PTZ)诱导的慢性癫痫大鼠的疗效及作用机制。
采用戊四氮(PTZ)水溶液(35mg/kg)建立癫痫大鼠模型。将大鼠分为 4 组,其中 3 组分别给予不同药物,每天 1 次,连续 28d,包括定痫丸(2.4g/kg)、VPA(0.2g/kg)或定痫丸(2.4g/kg)联合 VPA(0.2g/kg),对照组给予等体积生理盐水。根据动物行为、脑电图、Morris 水迷宫、免疫组织化学、转录组学和实时聚合酶链反应比较各组大鼠的差异。
与 VPA 单药组相比,定痫丸联合 VPA 治疗能更显著地抑制 PTZ 诱导的癫痫发作样行为,降低癫痫发作级别。与对照组相比,慢性 PTZ 诱导的癫痫大鼠的学习记忆能力在所有药物治疗组中均得到改善,在联合使用定痫丸和 VPA 的组中改善最为明显。与 MWM 测试结果相似,定痫丸和/或 VPA 治疗后神经兴奋性标志物基因 c-Fos 的表达减少,联合治疗组的效果最为显著。转录组学分析显示,与 VPA 单药治疗相比,定痫丸联合 VPA 治疗可上调与癫痫相关的啮齿动物海马基因表达。
本研究结果不仅强调了定痫丸联合 VPA 治疗的抗癫痫作用,还揭示了潜在的分子机制,并为应用中药治疗癫痫提供了一种方法。